Tessa Y S Le Large
Overview
Explore the profile of Tessa Y S Le Large including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
404
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Boyd L, Ali M, Puik J, Comandatore A, Ginocchi L, Meijer L, et al.
J Liq Biopsy
. 2025 Mar;
5:100152.
PMID: 40027944
Background: Novel biomarkers, such as plasma microRNAs (miRs), are needed to help guide clinical decision-making for the type of chemotherapy to use in patients with advanced pancreatic ductal adenocarcinoma (PDAC)....
2.
Rodriguez E, Zwart E, Affandi A, Verhoeff J, de Kok M, Boyd L, et al.
Cancer Sci
. 2024 Apr;
115(7):2170-2183.
PMID: 38686549
Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis with a 5-year survival of less than 10%. More knowledge of the immune response developed in patients with PDAC is pivotal to...
3.
Boyd L, Ali M, Comandatore A, Brandi G, Tavolari S, Gaeta R, et al.
BJS Open
. 2024 Apr;
8(2).
PMID: 38637298
No abstract available.
4.
A bile-based microRNA signature for differentiating malignant from benign pancreaticobiliary disease
Mato Prado M, Puik J, Castellano L, Lopez-Jimenez E, Liu D, Meijer L, et al.
Exp Hematol Oncol
. 2023 Dec;
12(1):101.
PMID: 38041102
Differentiating between pancreatic ductal adenocarcinoma (PDAC) and cholangiocarcinoma (CCA) is crucial for the appropriate course of treatment, especially with advancements in the role of neoadjuvant chemotherapies for PDAC, compared to...
5.
Boyd L, Nooijen L, Ali M, Puik J, Moustaquim J, Fraga Rodrigues S, et al.
Front Pharmacol
. 2023 Nov;
14:1274692.
PMID: 37920204
Effective (neo) adjuvant chemotherapy for cholangiocarcinoma is lacking due to chemoresistance and the absence of predictive biomarkers. Human equilibrative nucleoside transporter 1 (hENT1) has been described as a potential prognostic...
6.
Boyd L, Ali M, Comandatore A, Garajova I, Kam L, Puik J, et al.
JAMA Netw Open
. 2023 Aug;
6(8):e2331197.
PMID: 37639271
Importance: Accurate risk prediction models using routinely measured biomarkers-eg, carbohydrate antigen 19-9 (CA19-9) and bilirubin serum levels-for pancreatic cancer could facilitate early detection of pancreatic cancer and prevent potentially unnecessary...
7.
Boyd L, Ali M, Puik J, Meijer L, Le Large T, van Laarhoven H, et al.
Clin Cancer Res
. 2023 Aug;
29(15):2944.
PMID: 37525961
No abstract available.
8.
Maurer H, Garcia-Curiel A, Holmstrom S, Castillo C, Palermo C, Sastra S, et al.
bioRxiv
. 2023 Mar;
PMID: 36993718
To identify drivers of malignancy in human pancreatic ductal adenocarcinoma (PDAC), we performed regulatory network analysis on a large collection of expression profiles from laser capture microdissected samples of PDAC...
9.
Boyd L, Ali M, Leeflang M, Treglia G, de Vries R, Le Large T, et al.
EClinicalMedicine
. 2022 Dec;
55:101747.
PMID: 36457649
Background: Novel blood-based protein biomarkers may be of value for efficient, accurate, and non-invasive diagnosis of pancreatic cancer. This study assesses the diagnostic accuracy of newly recognized blood-based protein biomarkers...
10.
In t Veld S, Arkani M, Post E, Antunes-Ferreira M, DAmbrosi S, Vessies D, et al.
Cancer Cell
. 2022 Sep;
40(9):999-1009.e6.
PMID: 36055228
Cancer patients benefit from early tumor detection since treatment outcomes are more favorable for less advanced cancers. Platelets are involved in cancer progression and are considered a promising biosource for...